Centre de référence des maladies rénales rares Service de Néphrologie Rhumatologie Dermatologie Pédiatriques, Néphrogones, Filières ORKiD, Hôpital Femme Mère Enfant, Hospices Civils de Lyon,, 59 Boulevard Pinel, 69677, Bron Cedex, France.
Department of clinical epidemiology, EPICIME-CIC 1407 de Lyon, Inserm, CHU-Lyon, Bron, France.
Eur J Pediatr. 2020 Apr;179(4):661-669. doi: 10.1007/s00431-019-03553-y. Epub 2019 Dec 24.
Vitamin D deficiency is frequent in pediatric nephrology. The 2017 European guidelines recommend keeping 25OH vitamin D (25-D) levels within the 75-120 nmol/L range, ideally with daily supplementation. Intermittent supplementation with D3 has also been proposed. We aimed to assess the influence of our local protocol of intermittent vitamin D supplementation on the evolution of 25-D levels between baseline and 2 months. VITATOL is a prospective single-center study performed in our tertiary unit in children and teenagers followed for chronic kidney disease (CKD), kidney transplantation, or stable chronic nephrotic syndrome with 25-D levels below 75 nmol/L. Intermittent oral cholecalciferol (100,000 IU) was administered depending on baseline vitamin D levels and body weight. The primary outcome was the change in 25-D levels between baseline and 2 months. Secondary outcomes were the evolution of the main mineral biomarkers. Thirty-seven patients were included. Two months after beginning supplementation, corresponding to a median(min-max) of 46 (14-79) days after the last dose of vitamin D, 25-D levels increased from 50 to 76 nmol/L (p < 0.001), 18 patients having 25-D levels within the target range and 2 above. All patients displayed 25-D levels above 50 nmol/L. There were no significant changes in phosphate, PTH, alkaline phosphatase, and FGF23 levels before and after supplementation. Calcium levels increased from 2.39 to 2.44 mmol/L (p = 0.017), but no differences in calciuria and urinary calcium/creatinine ratio were observed.Conclusion: This vitamin D supplementation protocol using intermittent moderate doses of cholecalciferol seems efficient in 54% of cases, with neither significant overdose nor hypercalciuria. What is Known: • Vitamin D deficiency is frequent in pediatric nephrology. • The 2017 European guidelines recommend keeping 25OH vitamin D levels within the 75-120 nmol/L range ideally with daily supplementation, but intermittent supplementation with D3 has also been proposed. What is New: • We assessed the influence of a local protocol of intermittent vitamin D supplementation on the evolution of 25-D levels between baseline and 2 months in children and teenagers followed in pediatric nephrology. • The intermittent cholecalciferol supplementation protocol seems efficient in 54% of cases, with neither significant overdose nor hypercalciuria.
维生素 D 缺乏在儿科肾脏病学中很常见。2017 年欧洲指南建议将 25-羟维生素 D(25-D)水平保持在 75-120nmol/L 范围内,理想情况下每日补充。也建议间歇性补充 D3。我们旨在评估我们当地的间歇性维生素 D 补充方案对基线至 2 个月期间 25-D 水平变化的影响。VITATOL 是一项在我们的三级单位进行的前瞻性单中心研究,纳入了患有慢性肾脏病(CKD)、肾移植或稳定的慢性肾病综合征且 25-D 水平低于 75nmol/L 的儿童和青少年。根据基线维生素 D 水平和体重,给予间歇性口服胆钙化醇(100,000IU)。主要结局是基线至 2 个月期间 25-D 水平的变化。次要结局是主要矿物质生物标志物的演变。37 例患者入组。补充开始后 2 个月(最后一次维生素 D 剂量后中位数(最小值-最大值)46(14-79)天),25-D 水平从 50 增加到 76nmol/L(p<0.001),18 例患者的 25-D 水平在目标范围内,2 例以上。所有患者的 25-D 水平均高于 50nmol/L。补充前后磷酸盐、PTH、碱性磷酸酶和 FGF23 水平无显著变化。钙水平从 2.39 增加到 2.44mmol/L(p=0.017),但钙尿和尿钙/肌酐比值无差异。结论:使用间歇性中等剂量胆钙化醇的这种维生素 D 补充方案在 54%的病例中有效,既没有明显的过量也没有高钙尿症。已知:• 儿科肾脏病学中维生素 D 缺乏很常见。• 2017 年欧洲指南建议将 25-羟维生素 D 水平保持在 75-120nmol/L 范围内,理想情况下每日补充,但也建议间歇性补充 D3。新内容:• 我们评估了当地的间歇性维生素 D 补充方案对儿童和青少年在儿科肾脏病学中随访的基线至 2 个月期间 25-D 水平变化的影响。• 间歇性胆钙化醇补充方案在 54%的病例中有效,既没有明显的过量也没有高钙尿症。